Tislelizumab Combined With Concurrent Chemoradiotherapy as First-line Treatment for Stage IIIC2 Cervical Cancer
Clinical trial NCT05511623 · RECRUITING
Trial details
- NCT number
- NCT05511623
- Sponsor
- First Affiliated Hospital of Guangxi Medical University
- Status
- RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2022-09-01
- Primary completion
- 2024-12-31
- Enrollment
- 112
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.